Idexx Laboratories (IDXX) Q3 2025 10-Q Quarterly Report
Filed: Nov 3, 2025Period ending Sep 30, 2025
Health Care
In Vitro & In Vivo Diagnostic SubstancesSEC EDGAR Idexx Laboratories (IDXX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 3, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Idexx Laboratories Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • No quarterly revenue or YoY change information disclosed in this section
- • No profitability or margin percentages provided
Risk Factors
- • No material changes in risk factors since 2024 Annual Report
- • Ongoing risks include business, financial condition, or future results impact
Idexx Laboratories Q3 2025 Quarterly FinancialsXBRL
Revenue
$1.1B
▲ +13.3% YoY▼ -0.4% QoQ
Net Income
$275M
▲ +17.9% YoY▼ -6.6% QoQ
Gross Margin
61.8%
▲ +73bp YoY▼ -79bp QoQ
Operating Margin
32.1%
▲ +95bp YoY▼ -152bp QoQ
Net Margin
24.8%
▲ +98bp YoY▼ -165bp QoQ
ROE
17.6%
Total Assets
$3.4B
EPS (Diluted)
$3.40
▲ +21.0% YoY▼ -6.3% QoQ
Operating Cash Flow
$402M
▲ +82.8% YoY▲ +116.6% QoQ
Source: XBRL data from Idexx Laboratories Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Idexx Laboratories Quarterly Reports
Get deeper insights on Idexx Laboratories
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.